You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 4, 2024

RAZADYNE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Razadyne, and what generic alternatives are available?

Razadyne is a drug marketed by Janssen Pharms and is included in three NDAs.

The generic ingredient in RAZADYNE is galantamine hydrobromide. There are fifteen drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the galantamine hydrobromide profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Razadyne

A generic version of RAZADYNE was approved as galantamine hydrobromide by BARR on August 28th, 2008.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for RAZADYNE?
  • What are the global sales for RAZADYNE?
  • What is Average Wholesale Price for RAZADYNE?
Summary for RAZADYNE
US Patents:0
Applicants:1
NDAs:3
Raw Ingredient (Bulk) Api Vendors: 81
Clinical Trials: 21
Patent Applications: 4,904
Drug Prices: Drug price information for RAZADYNE
What excipients (inactive ingredients) are in RAZADYNE?RAZADYNE excipients list
DailyMed Link:RAZADYNE at DailyMed
Drug patent expirations by year for RAZADYNE
Drug Prices for RAZADYNE

See drug prices for RAZADYNE

Recent Clinical Trials for RAZADYNE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Vanderbilt University Medical CenterPhase 1
Doris Duke Charitable FoundationPhase 1/Phase 2
Vanderbilt University Medical CenterPhase 1/Phase 2

See all RAZADYNE clinical trials

Paragraph IV (Patent) Challenges for RAZADYNE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
RAZADYNE Tablets galantamine hydrobromide 4 mg, 8 mg and 12 mg 021169 14 2005-02-28

US Patents and Regulatory Information for RAZADYNE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Janssen Pharms RAZADYNE galantamine hydrobromide SOLUTION;ORAL 021224-001 Jun 22, 2001 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Janssen Pharms RAZADYNE ER galantamine hydrobromide CAPSULE, EXTENDED RELEASE;ORAL 021615-003 Apr 1, 2005 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Janssen Pharms RAZADYNE galantamine hydrobromide TABLET;ORAL 021169-003 Feb 28, 2001 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Janssen Pharms RAZADYNE galantamine hydrobromide TABLET;ORAL 021169-001 Feb 28, 2001 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Janssen Pharms RAZADYNE galantamine hydrobromide TABLET;ORAL 021169-002 Feb 28, 2001 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Janssen Pharms RAZADYNE ER galantamine hydrobromide CAPSULE, EXTENDED RELEASE;ORAL 021615-002 Apr 1, 2005 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Janssen Pharms RAZADYNE ER galantamine hydrobromide CAPSULE, EXTENDED RELEASE;ORAL 021615-001 Apr 1, 2005 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for RAZADYNE

International Patents for RAZADYNE

See the table below for patents covering RAZADYNE around the world.

Country Patent Number Title Estimated Expiration
Argentina 008237 TABLETA DE HIDROBROMURO DE GALANTAMINA DE DISOLUCION RAPIDA. ⤷  Sign Up
South Korea 100358676 ⤷  Sign Up
Spain 2235234 ⤷  Sign Up
Slovakia 169698 FAST-DISSOLVING GALANTHAMINE HYDROBROMIDE TABLET ⤷  Sign Up
China 1222077 ⤷  Sign Up
Finland 102756 ⤷  Sign Up
Hungary 9903476 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for RAZADYNE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0236684 C00236684/01 Switzerland ⤷  Sign Up FORMER REPRESENTANTIVE: E. BLUM AND CO. PATENTANWAELTE, CH
0236684 3/2001 Austria ⤷  Sign Up PRODUCT NAME: GALANTAMIN ODER SAEUREADDITIONSSALZE DAVON; NAT. REGISTRATION NO/DATE: 1-23748, 1-23749, 1-23750, 1-23751 20000822; FIRST REGISTRATION: SE 15561, 15562, 15563,15565 20000301
0236684 C300140 Netherlands ⤷  Sign Up PRODUCT NAME: GALANTAMINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZUURADDITIEZOUT, IN HET BIJZONDER GALANTAMINE HYDROBROMIDE; NAT. REGISTRATION NO/DATE: RVG 29073 - RVG 29076 20030702; FIRST REGISTRATION: SE 15561 - 15565 20000225
0236684 2001C/007 Belgium ⤷  Sign Up PRODUCT NAME: GALANTAMINUM HYDROBROMIDUM; NAT. REGISTRATION NO/DATE: 1028 IS 94 F3 20000918; FIRST REGISTRATION: SE 15561 20000301
0236684 SPC/GB00/033 United Kingdom ⤷  Sign Up PRODUCT NAME: GALANTHAMINE OR ACID ADDITION SALTS THEREOF; REGISTERED: SE 15561 20000301; SE 15562 20000301; SE 15563 20000301; SE 15565 20000301; UK PL08557/0039 20000914; UK PL08557/0040 20000914; UK PL08557/0041 20000914; UK PL08557/0042 20000914
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.